Cargando...
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...
Gardado en:
| Publicado en: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5006894/ https://ncbi.nlm.nih.gov/pubmed/27622011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1052212 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|